Oncology company ORIC Pharmaceuticals has completed a $50m Series C preferred stock financing to support advancement of its ORIC-101 against treatment-resistant solid tumours, as well as continued progress on mechanisms of resistance in cancer.

With the new financing, the total equity capital raised by the company has increased to more than $119m.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Fidelity Management & Research Company, Trinitas Capital, Taiho Ventures, and NS Investment are the new investors in the Series C.

The company’s investors, including The Column Group, Topspin Fund, OrbiMed, Memorial Sloan Kettering Cancer Center, EcoR1 Capital, Kravis Investment Partners, and Foresite Capital also participated in the financing.

ORIC-101, the company’s lead asset, is a potent small-molecule inhibitor of the glucocorticoid receptor (GR) and the subject of an ongoing Phase I trial.

“With our Series C financing we are very pleased to have both the continued support of our previous investors and expand our investor base with leading investors.”

ORIC Pharmaceuticals CEO and board member Richard Heyman said: “Treatment-resistant cancers are a large unmet medical need. With our Series C financing we are very pleased to have both the continued support of our previous investors and expand our investor base with leading investors.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Their support, combined with ORIC’s commitment to discovering and developing new therapeutics targeting cancer, allows the company to build on the strong foundation of our co-founders, advisors and internal team, and provides for long-term success.”

The company also plans to pursue clinical development of the inhibitor in patients with treatment-resistant solid tumours combining with immuno-oncology treatments and chemotherapy.

ORIC also plans to use the investment to support its research and pipeline programmes that target mechanisms of resistance in cancer.